Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype?
by Andy Pickett
The Botulinum J. (TBJ), Vol. 2, No. 3/4, 2013

Abstract: The basis of botulinum toxin use as a neuromedicine started over 40 years ago when the first serotype was chosen for key initial studies in monkeys by Alan Scott and colleagues in the USA. From that point on, the protein has been used extensively and worldwide for treatment of many clinical conditions. But much remains to be documented about the earliest times, the very beginning years when critical choices and decisions were made. This first article in a series looks at the choice of the first botulinum toxin serotype used and why that choice was made.

Online publication date: Sat, 11-Oct-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the The Botulinum J. (TBJ):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com